Post-earnings recap
Reported
Wed, Nov 6, 2024
EPS actual
$-0.33
EPS est.
$-0.42
EPS surprise
+21.43%
1-day move
+3.87%
—
Est. EPS
—
Est. Rev
—
Impl. Move
—
Arcutis Biotherapeutics reported a better-than-expected EPS for Q3-2024, which contributed to a positive stock reaction, with shares rising by 3.87%. The company did not disclose revenue figures or future guidance, leaving some uncertainty about its financial outlook. Investors may be encouraged by the EPS surprise, but the lack of additional details could lead to cautious sentiment.
| Metric | Actual | Expected | Surprise |
|---|---|---|---|
| EPS | -$0.33 | N/A | +21.43% |
| Revenue | N/A | N/A | N/A |
Management expressed satisfaction with the EPS results despite not providing revenue figures. They emphasized their commitment to product development.
We are pleased with our EPS performance this quarter.
Our focus remains on advancing our product pipeline.